Recent
quick returnPopular searches
live pathsTECHi Search
Tickers, tools, analysts, companies, products, and every story in the archive — one search, ranked by relevance.
Stories from the archive
Barclays upgraded Marvell to Overweight with a $150 target; MRVL prints all-time high $129.84 as AI optical thesis and Nvidia $2B anchor deal reshape the story.
AMD’s ZT Systems and Sanmina moves create a sharper stock question: can Helios turn open AI racks into high-quality gross profit?
Expert analysis of the notable tech stocks for 2026. Magnificent Seven rankings, AI chip plays, semiconductor picks and emerging tech investments.
Oracle's bold AI forecast and partnerships have sent its stock soaring. Discover how its cloud infrastructure growth and AI ambitions are positioning Oracle against competitors like AWS and Azure.
Shares of Micron Technology rose 5.08% on March 13, 2026, as opposed to wider market fall. As rising oil prices put pressure on stocks, the S&P 500
Adobe announced its stocks decreased over 65% within the context of the earnings announcement, an emphasis on the increased susceptibility of investor
The equity of Nvidia has improved at a considerable pace, escalating by about half in the past year, a trend that has been linked to its superiority in
The share price of Micron improved again after new evidence showed that the demand for high-bandwidth memory remains higher than the supply.
Samsung's founding family plans $1.2B share sale amid stock surge, driven by AI chip demand and inheritance tax obligations. Market impact expected to be limited.
Iran reclosed Hormuz and the US seized Iran-flagged Touska. Oil near $88. Here is what it actually does to Apple, NVIDIA, Microsoft, and the AI tape.
SK Hynix accelerates HBM production to meet surging AI memory demand, commanding 62% market share. With $650B in US AI spending and sold-out 2026 stock, profits could exceed $100B won.
Atlassian shares fell 39% to $86.99 despite $1.60B Q2 revenue (+23% YoY). Trading at lowest P/S ratio since 2015. AI coding tools pose risks, but long-term outlook remains strong for patient investors.
